Archives

  • Volume 5, Issue 4, Winter 2024

    • Systemic Sclerosis: Pathogenesis, Diagnosis, and Management
    • New Treatments for Acne Vulgaris Over the Past Decade
    • Paradoxical Psoriasis Induced by TNF Inhibitors and Beyond: A Review
    • Highlights from the 33rd Congress of the European Academy of Dermatology and Venereology (EADV)
    • Practical Tips for Treating Pediatric Dermatology Patients

  • Volume 5, Issue 3, Fall 2024

    • Management and Treatment of Neurofibromatosis Type I
    • Updates and Pearls from the Society of Pediatric Dermatology Meeting
    • Keratinocyte Carcinoma: Canadian Landscape and an Evidence-based Approach to Follow-up
    • Low-tech Treatments for Acne Scarring: CROSS, Subcision, and Injectables
    • Dermatology Treatments and their Effects on Patch Testing

  • Volume 5, Issue 2, Summer 2024

    • Dutasteride Mesotherapy for Androgenetic Alopecia: What do we know?
    • Oral Lichen Planus: An Overview
    • Keloids: Review of Pathogenesis and Evidence‑Based Treatment Modalities
    • Update on Chronic Hand Eczema
    • Similarities and Differences in Biosimilars: A Literature Review and Summary

  • Special Supplement, April 2024

    • Using IL-17s for the Treatment of Psoriasis in 2024: A Roundtable Discussion

  • Volume 5, Issue 1, March 2024

    • Advances in Vitiligo: Pathophysiology, Psychosocial Impact and Emerging Therapy
    • Simple Superficial Chemical Peels to Complement a Medical Dermatology Practice
    • Clinical Manifestations and Treatment of Ocular Rosacea
    • Cutaneous Manifestations of IBD: Potential Role of Vedolizumab
    • A Literature Review of COVID 19 Vaccination and Lichen Planus Pigmentosus: Is There a Correlation?

  • Volume 4, Issue 4, December 2023

    • Hidradenitis Supparativa Management: An Overview
    • Field Cancerization: Beyond Topical Agents
    • Dermatologic Care for the LGBT Population: Terminology, Strategies & Select Diseases
    • Autoimmune Rheumatic Disease with Cutaneous Manifestations in North American Indigenous Populations: A Review of Regional Prevalence Data and Disease Characteristics
    • Highlights from the Inflammatory Skin Disease Summit 2023 in Vienna, Austria

  • Special Supplement October 2023

    • Evaulating The Durability of Response in New Biologics for Psoriasis

  • Volume 4, Issue 3, September 2023

    • Tebentafusp: A New Systemic Treatment for Unresectable or Metastatic Uveal Melanoma in HLA-A*02:01-Positive Patients
    • Psoriasiform and Eczematous Paradoxical Reactions to Biologic Agents
    • Use of Neuromodulators as Aesthetic Treatment in the Lower Face
    • A Practical Guide to Non-insured Health Benefits (NIHB) for Dermatologists Caring for Status First Nations and Inuit Peoples of Canada
    • Strategies to Optimize Outcomes and Prevent Complications with Lasers

  • Volume 4, Issue 2, June 2023

    • Advanced Therapies for Moderate-to-Severe Atopic Dermatitis: Marathon or Sprint?
    • Mycosis Fungoides: Assessment and Management
    • Virtual Dermatologic Care in Rural and Remote Canadian Indigenous Communities: Balancing Cost, Quality and Access
    • How Network Meta-Analysis Informs Systemic Treatments for Atopic Dermatitis
    • Update on the Classification and Management of Cutaneous Lupus Erythematosus

  • Volume 4, Issue 1, March 2023

    • Management of Cutaneous Mastocytosis
    • Answering 10 Burning Questions on Fractional Resurfacing
    • In Brief: Laboratory and Clinical Monitoring Requirements for JAK Inhibitors
    • Bacterial Skin Infection Burdens in Northern and Rural Canadian Indigenous Communities: A Review of National and Regional Data, and Evidence-Based Solutions
    • Three Essential Skincare Product Ingredients

  • Special Supplement, January 2023

    • A Review of Metvix for the Treatment of Actinic Keratoses, Superficial Basal Cell Carcinoma and for Use in Daylight Photodynamic Therapy

  • Volume 3, Issue 4, December 2022

    • Systemic Treatments for Non-Melanoma Skin Cancers
    • Beyond the Double-Chin: The Use of Deoxycholic Acid for Non-Submental Fat Reduction
    • Practical Considerations in Antihistamine Selection
    • Platelet-Rich Plasma (PRP) in Aesthetic Dermatology
    • Topical Treatment Options for Field Cancerization

  • Special Supplement, November 2022

    • A Randomized Withdrawal Study with Rescue Treatment in Patients with Protocol Defined Flare: Reviewing Jade Regimen

  • Special Supplement, October 2022

    • Long-term Topical Management of Plaque Psoriasis: A Review of the Data on Proactive Maintenance with Cal/BD Foam

  • Special Supplement, September 2022

    • What to Know About JAK Inhibitors

  • Volume 3, Issue 3, September 2022

    • Palmoplantar Pustular Psoriasis: An Update on Pathophysiology and Review of Treatment Options
    • New Trends in Pediatric Antihistamine Use
    • Morphea Through the Ages
    • Staying Ahead of Dupilumab-Associated Ocular Surface Disease
    • Poly-L-Lactic Acid for Global Facial Volumization
    • Dermatologic Immune-Related Adverse Events With Immune Checkpoint Inhibitors

  • Volume 3, Issue 2, May 2022

    • Cutaneous Squamous Cell Carcinoma: Risk Stratification and Staging
    • Dropping the Delay: Safety of Procedural Interventions During and After Isotretinoin Use
    • Strategies and Techniques for Minimizing Surgical Scars Following Dermatologic Procedures and Excisions
    • Cosmetic Injectable Treatments in Skin of Colour
    • Seeing Red: Pearls for Vascular Laser Treatment
    • Approach to Skin Lesions in Patients with Inflammatory Bowel Diseases

  • Volume 3, Issue 1, March 2022

    • Bullous Pemphigoid: Current and Emerging Therapies
    • Diluted and Hyperdiluted Calcium Hydroxyapatite For Skin Tightening
    • IL-17 Inhibitors and the Risk of Malignancy
    • Post-Inflammatory Hyperpigmentation: Pathogenesis, Diagnosis, and Treatment
    • An Overview of Rosacea
    • JAK-STAT Pathway Inhibitors: A New Jackpot for Dermatology

  • Special Supplement, February 2022

    • An Update on the Fixed-Dose Combination Topical Corticosteroid/Vitamin D3 Analogue (Betamethasone Dipropionate-Calcipotriol) for Plaque Psoriasis
    • Itching For Relief: The Evidence Of Fixed Dose Calcipotriol Plus Betamethasone Dipropionate Foam For Psoriasis
    • The Evolution Of Cal/BD Fixed Dose Combination Therapy For Psoriasis: A Case Study And Discussion

  • Volume 2, Issue 4, December 2021

    • Non-Invasive Diagnostic Technologies for Melanoma
    • Approach to Diagnosis and Management of Reactive Infectious Mucosal Eruption (RIME)
    • Skipping the Scalpel: Updates On Non-Invasive Skin Tightening
    • Onychomycosis
    • Prurigo Nodularis
    • The Current Landscape of Artificial Intelligence in Dermatology

  • Special Supplement, September 2021

    • Tildrakizumab For PsA
    • Tildrakizumab In PsA: A Data Review

  • Volume 2, Issue 3, August 2021

    • Scar Injection: Beyond Triamcinolone Acetonide
    • My Approach To Complementary and Natural Therapies In Managing Atopic Dermatitis
    • Treating Adult Female Acne
    • What To Know About COVID-19 And Its Impact On Patients With Psoriasis
    • Reconstituting Neuromodulators In Clinical Practice
    • Skin On Social: The Influence Of Social Media On Dermatology

  • Special Supplement, June 2021

    • Understanding Cumulative Life Course Impairment in Psoriasis: Impact On Patient Management

  • Volume 2, Issue 2, May 2021

    • What’s New and Old in Treatments for Pediatric Dermatology
    • An Overview of Lichen Sclerosus
    • An Update on Treatments for Lichen Planopilaris
    • Oral Supplementation in Dermatology
    • New Anatomical Insights Into Preventing Brow Ptosis with Botulinum Toxin-A Use
    • Panning for Pandemic Gold: Personal Lessons and Observation

  • Special Supplement, March 2021

    • The Era of IL-23: Introduction of Tildrakizumab
    • Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Review
    • Tildrakizumab in Patients with Metabolic Syndrome: A Novel Approach
1-25 of 30